Clinical Rheumatology

, Volume 33, Issue 1, pp 137–139

Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases

  • C. Sengler
  • M. Niewerth
  • T. Kallinich
  • A. Nimtz-Talaska
  • M. Haller
  • H.-I. Huppertz
  • K. Minden
Brief Report

Abstract

The objective of this study is to evaluate complications and changes in health status (disease activity and flare) in response to the AS03-adjuvanted H1N1 vaccine in children with rheumatic diseases. We conducted a nationwide survey addressing paediatric rheumatology sites who participated in the national paediatric rheumatology database. Ninety patients were documented—38 % under treatment with biologicals—of whom 18 % suffered from complications (10 % local and 8 % systemic) with no relevant changes in median disease activity or flare rate during 4 weeks following the vaccination. The adjuvanted H1N1 influenza vaccine seems to be adequately tolerated in children with rheumatic diseases.

Keywords

Children Disease activity Flare H1N1 influenza vaccination Rheumatic disease 

References

  1. 1.
    Epidemiologisches Bulletin (2009) STIKO-Empfehlung zur Impfung gegen die Neue Influenza A (H1N1). Epidemiologisches Bulletin Nr. 41/2009. Robert-Koch-Institut, BerlinGoogle Scholar
  2. 2.
    Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Tsitsami E, Kyriazopoulou-Dalaina V (2001) Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol 19:589–594PubMedGoogle Scholar
  3. 3.
    Malleson PN, Tekano JL, Scheifele DW, Weber JM (1993) Influenza immunization in children with chronic arthritis: a prospective study. J Rheumatol 20:1769–1773PubMedGoogle Scholar
  4. 4.
    Ogimi C, Tanaka R, Saitoh A, Oh-Ishi T (2011) Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr Infect Dis J 30:208–211PubMedCrossRefGoogle Scholar
  5. 5.
    Hoyeraal HM, Mellbye OJ (1974) Humoral immunity in juvenile rheumatoid arthritis. Ann Rheum Dis 33:248–254PubMedCrossRefGoogle Scholar
  6. 6.
    Zonneveld-Huijssoon E, Ronaghy A, Van Rossum MA, Rijkers GT, van der Klis FR, Sanders EA, Vermeer-De Bondt PE, Hoes AW, van der Net JJ, Engels C, Kuis W, Prakken BJ, Van Tol MJ, Wulffraat NM (2007) Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis. Arthritis Rheum 56:639–646PubMedCrossRefGoogle Scholar
  7. 7.
    Aikawa NE, Campos LM, Goldenstein-Schainberg C, Saad CG, Ribeiro AC, Bueno C, Precioso AR, Timenetsky MC, Silva CA, Bonfa E (2013) Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis. Scand J Rheumatol 42:34–40PubMedCrossRefGoogle Scholar
  8. 8.
    Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM (2010) Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 28:1740–1745PubMedCrossRefGoogle Scholar
  9. 9.
    Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston PE, Allen RJ, Okike I, Ladhani S, Sheasby E, Hoschler K, Andrews N, Waight P, Collinson AC, Heath PT, Finn A, Faust SN, Snape MD, Miller E, Pollard AJ (2010) Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 340:c2649PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, Grillet S, Seebach JD, Kaiser L, Wunderli W, Guerne PA, Siegrist CA (2011) Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 63:1486–1496PubMedCrossRefGoogle Scholar
  11. 11.
    Dell'era L, Corona F, Daleno C, Scala A, Principi N, Esposito S (2012) Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. Vaccine 30:936–940PubMedCrossRefGoogle Scholar
  12. 12.
    Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, Armbrust W, Hoppenreijs EP, Uiterwaal CS, Kuis W, Wulffraat NM (2007) Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis 66:1384–1387PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2013

Authors and Affiliations

  • C. Sengler
    • 1
  • M. Niewerth
    • 1
  • T. Kallinich
    • 2
  • A. Nimtz-Talaska
    • 3
  • M. Haller
    • 4
  • H.-I. Huppertz
    • 5
  • K. Minden
    • 1
  1. 1.Epidemiology UnitGerman Rheumatism Research Centre Berlin, Leibniz InstituteBerlinGermany
  2. 2.Children’s University Hospital, Department of Pediatric Pneumology and ImmunologyCharité—Universitätsmedizin BerlinBerlinGermany
  3. 3.Pediatrician/Pediatric Rheumatologist in Private PracticeFrankfurt/OderGermany
  4. 4.Pediatrician/Pediatric Rheumatologist in Private PracticeGundelfingenGermany
  5. 5.Klinikum Bremen MitteBremenGermany

Personalised recommendations